Brainstorm Cell Therapeutics Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (32)

View All

Latest Posts

About This Stock More About This Stock
Why Radicava Approval Is Good News For BrainStorm Cell Therapeutics
Article By: Jason Napodano
Tuesday, May 9, 2017 10:13 AM EDT
BrainStorm is expanding its management team and focusing on securing non-dilutive capital. The company has the cash to begin the study and an excellent track record of bringing in non-dilutive grants to keep shareholder dilution to a minimum.
In this article: BCLI
Read
NurOwn Shows Potential In Preclinical Autism Model
Article By: Jason Napodano
Wednesday, April 19, 2017 1:20 PM EDT
BrainStorm’s next step in the development of NurOwn is to initiate a Phase 3 clinical study in the U.S. This will be a major milestone for the company and establish an important Catalyst for the shares once initiated.
In this article: BCLI
Read
BrainStorm Strengthens Management Team, Expands Board
Article By: Jason Napodano
Monday, March 6, 2017 3:12 PM EDT
BrainStorm’s next step in the development of NurOwn is to initiate a Phase 3 clinical study in the U.S. This will be a major milestone for the company and establish an important Catalyst for the shares once initiated.
In this article: BCLI
Read
Time To Go Long Brainstorm Cell Therapeutics?
Article By: Jason Napodano
Wednesday, January 18, 2017 10:52 AM EDT
The similarities in strategy and data between Brainstorm, Bluebird and Sarepta are striking. The discrepancies in valuation present an opportunity.
In this article: BCLI, SRPT, BLUE Also: CUR, D-STEM (DEFUNCT)
Read
Interview With Neurologist And ALS KOL Sheds Light On Brainstorm's Potential With NurOwn
Article By: Jason Napodano
Monday, November 28, 2016 1:05 PM EDT
BrainStorm stock is looking extremely interesting to me at this level. Investor concerns over an imminent massive dilutive offering are misguided. BrainStorm entered October 2016 with $11.2 million in cash.
In this article: BCLI
Read
All Posts

Latest Tweets for $BCLI

No tweets yet!

PARTNER HEADLINES